Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

469
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
469
In Vitro Drug Dissolution: Alternative Methods01:17

In Vitro Drug Dissolution: Alternative Methods

322
Alternative drug dissolution methods include the rotating bottle, intrinsic dissolution test, peristalsis, and the Franz diffusion cell method. The rotating bottle method involves meticulously rotating tightly capped controlled-release beads in a temperature-controlled bath. Periodic decanting of samples allows for residue assay, followed by refilling with fresh medium and testing at various pH levels to emulate the gastrointestinal tract conditions.In contrast, the intrinsic dissolution test...
322
In Vitro Drug Dissolution: Compendial Testing Models II01:09

In Vitro Drug Dissolution: Compendial Testing Models II

466
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
466
In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

427
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
427
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

345
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
345
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

74
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Density Lipoprotein Nanoparticles Delivering Liver X Receptor Agonist for the Treatment of Age-Related Macular Degeneration.

Molecular pharmaceutics·2026
Same author

Intermetallic nanoassemblies potentiate systemic STING activation.

Science (New York, N.Y.)·2026
Same author

Mastering particle size analysis: lessons, challenges, and future directions from the FDA-CRCG workshop.

AAPS open·2026
Same author

"Targeting NF-κB epigenetic activation and DNA repair deficiency in G34-mutant pediatric diffuse hemispheric glioma with nanoparticles combining PARP inhibition and immune stimulation mediated by CpG dinucleotides".

bioRxiv : the preprint server for biology·2026
Same author

Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products.

The AAPS journal·2026
Same author

Engineered polysaccharides for controlling innate and adaptive immune responses.

Nature reviews bioengineering·2025

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Asymmetric Field Flow Fractionation for Bioreactor Integration
06:28

Author Spotlight: Asymmetric Field Flow Fractionation for Bioreactor Integration

Published on: February 2, 2024

1.5K

Development of an In Vitro Release Test to Characterize Onivyde® Using Bio-Beads SM-2 Resin.

Vivian Juang1,2, May Thazin Phoo1,2, Hsiu-Wei Yang1,2

  • 1Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan, 48109, USA.

The AAPS Journal
|March 14, 2026
PubMed
Summary

A new in vitro release test (IVRT) using Bio-Beads SM-2 Resin was developed for generic irinotecan liposome injection. This method offers a robust and sensitive platform for quality control and regulatory evaluation.

Keywords:
in vitro release testIVRTbio-Beads SM-2 resinirinotecan liposome injectiononivyde

More Related Videos

Mammalian Cell Encapsulation in Alginate Beads Using a Simple Stirred Vessel
10:20

Mammalian Cell Encapsulation in Alginate Beads Using a Simple Stirred Vessel

Published on: June 29, 2017

20.8K
Fluorescence Biomembrane Force Probe: Concurrent Quantitation of Receptor-ligand Kinetics and Binding-induced Intracellular Signaling on a Single Cell
14:09

Fluorescence Biomembrane Force Probe: Concurrent Quantitation of Receptor-ligand Kinetics and Binding-induced Intracellular Signaling on a Single Cell

Published on: August 4, 2015

13.1K

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Asymmetric Field Flow Fractionation for Bioreactor Integration
06:28

Author Spotlight: Asymmetric Field Flow Fractionation for Bioreactor Integration

Published on: February 2, 2024

1.5K
Mammalian Cell Encapsulation in Alginate Beads Using a Simple Stirred Vessel
10:20

Mammalian Cell Encapsulation in Alginate Beads Using a Simple Stirred Vessel

Published on: June 29, 2017

20.8K
Fluorescence Biomembrane Force Probe: Concurrent Quantitation of Receptor-ligand Kinetics and Binding-induced Intracellular Signaling on a Single Cell
14:09

Fluorescence Biomembrane Force Probe: Concurrent Quantitation of Receptor-ligand Kinetics and Binding-induced Intracellular Signaling on a Single Cell

Published on: August 4, 2015

13.1K

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Analytical Chemistry

Background:

  • Generic Onivyde® (irinotecan liposome injection) development necessitates a reliable in vitro release test (IVRT).
  • Conventional dialysis-based IVRT methods face limitations in maintaining sink conditions and exhibit variability.
  • Challenges include membrane interference and batch inconsistencies in existing IVRT protocols.

Purpose of the Study:

  • To develop and optimize a novel, discriminative IVRT for irinotecan liposome injection.
  • To overcome the limitations of traditional dialysis-based IVRT methods.
  • To establish a robust platform for quality control and regulatory assessment of generic liposomal irinotecan formulations.

Main Methods:

  • An IVRT utilizing Bio-Beads SM-2 Resin was designed to adsorb free irinotecan via hydrophobic interactions.
  • Key parameters including BioBeads concentration, agitation, temperature, and formulation concentration were systematically optimized.
  • Optimized conditions involved 50 mg/mL BioBeads, vertical rotation at 10 rpm, 25°C, and 45 µg/mL Onivyde® concentration.

Main Results:

  • The optimized BioBeads-based IVRT achieved >90% drug release within 24 hours with minimal liposomal disruption.
  • Mechanical agitation was identified as the most significant factor influencing release kinetics.
  • The method demonstrated high reproducibility, effectively distinguished between stressed and non-stressed formulations, and maintained sink conditions.

Conclusions:

  • The BioBeads-based IVRT provides a practical, robust, and sensitive alternative to dialysis-based methods.
  • This platform simplifies sample handling and eliminates membrane-related diffusion limitations.
  • The developed IVRT is well-suited for accelerated release testing and quality control in generic drug development and regulatory evaluation.